tirzepatide cvot SURPASS-CVOT: Significantly Reduces Major Kidney Events Compared to Dulaglutide in T2D SURPASS-CVOT Published: Large Trial Confirms

Klebanoff: Medicaid programs are not required to cover drugs for weight loss, even if FDA-approved

Additionally, some symptoms resembling hot flashes could potentially be related to other factors

PIONEER 4 PIONEER 4 was an important trial comparing the addition of oral semaglutide or liraglutide to background metformin with or without an SGLT-2 inhibitor in patients with T2DM

5 mg weekly: Average 16% total body weight reduction over 72 weeks 10 mg weekly: Average 21.4% total body weight reduction 15 mg weekly: Average 22.5% total body weight reduction Placebo: Average 2.4% reduction These are remarkable numbers

There are genuine physiological reasons to ensure adequate B12 status during GLP-1 receptor agonist therapy, even if the delivery method of combining them in one vial is now being questioned

focusing first on these concrete causes narrows the problem fast